Themison is a Danish Health Tech startup developing a patient-centric clinical trial platform to help pharmaceutical companies, Contract Research Organizations, and Clinical Trial sites solve the high dropout rates and engagement issues in clinical trials with its innovative Behavioral Algorithm and personalized patient engagement tools. Themison tackles the critical challenge of patient attrition in clinical trials, which significantly impacts the cost and timeline of drug development. This problem is widespread, affecting virtually all clinical trials globally, with dropout rates nearing 30% and substantial costs associated with replacing each patient (20k-100k USD x patient). These challenges not only delay the introduction of new treatments but also impose financial and operational burdens on our customers, threatening their competitive edge and the successful market introduction of new therapies. Themison addresses this challenge through a unique blend of technology and patient-centric design. Our platform features an admin portal with an engagement analytics dashboard for trial managers to preempt dropouts and a mobile app for patients with demographic-specific interfaces. This comprehensive approach simplifies trial protocols and enhances patient engagement through intelligent scheduling, journey maps, notifications, reminders, and a chat functionality. Central to our solution is the Behavioral Algorithm, providing deep insights into patient behavior, which in turn helps refine trial designs, optimize recruitment strategies, and improve treatment adherence. Our integration capabilities further tailor the trial experience to meet the unique needs of different demographics, ensuring each trial is as effective and efficient as possible. The inception of Themison was driven by a recognition of the significant inefficiencies and patient engagement challenges within the clinical trial industry. Observing the direct and indirect costs associated with high dropout rates, the delay in getting treatments to market, and the overall negative impact on public health motivated our team. With backgrounds in technology, healthcare, and data analytics, we were uniquely positioned to tackle this issue head-on. The lack of existing solutions that effectively address patient engagement and dropout rates, combined with our passion for innovation and making a meaningful impact in healthcare, propelled us to develop Themison. Our goal is to revolutionize clinical trials, making them more efficient, cost-effective, and patient-centric, ultimately accelerating the delivery of new treatments to those who need them most.